- The FDA's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee have voted 15 - 5 (1 abstain) in favor that the results from the large-scale Phase 4 PRECISION study demonstrated comparable cardiovascular safety of Pfizer's (PFE -0.8%) arthritis med CELEBREX (celecoxib) to naproxen (Aleve) and ibuprofen (Motrin).
- If formerly approved by the FDA, which seems likely, the data will be added to the labeling of CELEBREX.